H-Index
14
Scimago Lab
powered by Scopus
eISSN: 2373-3586
call: +1.631.629.4328
Mon-Fri 10 am - 2 pm EST

Logo

Medical Science Monitor Basic Research
MSM

Annals
ISI-Home

Metastatic Anaplastic Lymphoma Kinase-1 (ALK-1)-Rearranged Inflammatory Myofibroblastic Sarcoma to the Brain with Leptomeningeal Involvement: Favorable Response to Serial ALK Inhibitors: A Case Report

Cai Yuan, Muchou J. Ma, John V. Parker, Tarek M. Mekhail

Department of Internal Medicine, Florida Hospital Internal Medicine Residency, Orlando, FL, USA

Am J Case Rep 2017; 18:799-804

DOI: 10.12659/AJCR.903698

Available online:

Published: 2017-07-17


BACKGROUND: ALK gene rearrangements as oncogenic drivers have been described in many cancers, including inflammatory myofibroblastic sarcoma (IMS). The first-generation ALK inhibitor was limited in its ability to cross the blood-brain-barrier to treat brain metastasis. Drug-resistance invariably develops over time in ALK-rearranged tumors, which leads to disease progression. The newer generations of ALK inhibitors are designed to have higher potency in ALK inhibition and improved CNS penetration.
CASE REPORT: We report a rare case of pulmonary IMS with ALK-1 gene rearrangement and multiple brain metastases as initial presentation. After the primary lung tumor and the larger brain metastases were resected, control of residual CNS disease and subsequent progression and CNS spread was achieved with favorable clinical response by all three generations of ALK inhibitors.
CONCLUSIONS: ALK inhibitors may be an effective therapy for this rare and unusual form of ALK-1-rearranged cancer, even in the presence of multifocal CNS metastases with leptomeningeal involvement.

Keywords: Gene Rearrangement, Neoplasm Metastasis, Sarcoma



Back